Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization
- 129 Downloads
To evaluate contrast sensitivity (CS) using Pelli-Robson charts after intravitreal ranibizumab (IVR) (Lucentis, Novartis, Basel, Switzerland) or bevacizumab (IVB) (Avastin, Genentech, South San Francisco, California, USA) in eyes with myopic choroidal neovascularization (mCNV).
A retrospective review was performed of 17 consecutive patients treated with IVR (n = 10; 0.5 mg) or IVB (n = 7; 1.25 mg) for mCNV from July, 2006 with follow-ups through September, 2009. Re-treatment was performed at monthly or longer intervals if there was fluorescein leakage in fluorescein angiogram (FAG) and or apparent subretinal fluid in optical coherence tomography (OCT) persisted.
CS improved by a mean of one letter at 1 month (n = 17; p = 0.32), four letters at 3 months (n = 17; p = 0.02), four letters at 6 months (n = 15; p = 0.01), five letters at 9 months (n = 14; p = 0.04) and six letters at 12 months (n = 13; p = 0.03). The mean number of IVR/IVB was 1.6/1.6, 2.6/2.3, 3.1/3.2, 4.1/4.2 and 4.5/4.6 at 1 month, 3 months, 6 months, 9 months, and 12 months, respectively.
Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV.
KeywordsBevacizumab Myopic choroidal neovascularization Pelli-Robson contrast sensitivity Ranibizumab
Conflicts of interest
The authors have no conflict of interests to declare.
No financial support was provided for this study.
- 10.Rubin GS (1988) Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci 2:169–177Google Scholar
- 12.Rubin GS, Bandeen-Roche K, Huang GH, Munoz B, Schein OD, Fried LP, West SK (2001) The association of multiple visual impairments with self report visual disability: SEE project. Invest Ophthalm Vis Sci 42:64–72Google Scholar